FILSPARI (sparsentan) – Decreases in Hemoglobin

FILSPARI (sparsentan) – Risk Evaluation and Mitigation Strategy (REMS)

FILSPARI (sparsentan) – Mechanism of Action and Pharmacology

FILSPARI (sparsentan) – Effect on Proteinuria in IgA Nephropathy

FILSPARI (sparsentan): Elevated Liver Transaminases and Hepatic Safety Results

FILSPARI (sparsentan) – In Combination With SGLT2 Inhibitors in IgA Nephropathy

FILSPARI (sparsentan) – Concomitant Medications Included in Clinical Trials

FILSPARI (sparsentan) – Changes in Blood Pressure and Hypotensive Events

FILSPARI (sparsentan) – Use with Diuretics in IgA Nephropathy and FSGS

FILSPARI (sparsentan) – In Combination With Immunosuppressant Therapy in IgA Nephropathy

FILSPARI (sparsentan) – Transitioning from ACEi/ARB Treatment to Sparsentan in Clinical Trials

FILSPARI (sparsentan) – Dosing and Administration in Clinical Trials

FILSPARI (sparsentan) – Safety in Clinical Trials